Scailyte develops artificial intelligence technology for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into diseases by uncovering human's hidden "single-cell"? secrets. Our AI-based software ScaiVision offers best-in-class performance for supervised pattern recognition analysis of single-cell data. The performance and clinically-relevant application of the deep learning algorithm have been demonstrated in a scientific publication by our co-founder Prof. Claassen (ETH Zurich). ScaiVision will allow our customers to reduce data analysis time and costs, while increasing groundbreaking insights.
Moreover, we are also providing biomarker discovery services leveraging our expertise in single-cell technologies and our AI-based data analytics solutions. We support pharmaceutical companies during the drug discovery & development process by introducing and implementing single-cell approaches for the discovery of novel disease mechanisms, as well as the discovery of biomarkers for drug efficacy, toxicity, and patient stratification.
B2B
1 to 25
Series A
$6,889,835
Scaling Up
2017
Pharmaceuticals
Managed Health Care
Healthcare
Biotechnology
N/A
Increase Efficiency
Analytics
Service
Yes
Active
Machine Learning
Software
N/A
